Parcourir par sujet "antivirus agent"

Aiming towards hepatitis C virus elimination in Greece

Papatheodoridis G.V., Goulis J., Sypsa V., Lionis C., Manolakopoulos S., Elefsiniotis I., Anagnostou O., Tsoulas C., Hatzakis A., Dalekos G.N. (2019)

There are estimated to be 74,000-134,000 patients living with chronic hepatitis C in Greece, but only 20-30% of them are aware of their disease status. In July 2017, the Hellenic National Plan for Hepatitis C was announced ...

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis

Fan R., Papatheodoridis G., Sun J., Innes H., Toyoda H., Xie Q., Mo S., Sypsa V., Guha I.N., Kumada T., Niu J., Dalekos G., Yasuda S., Barnes E., Lian J., Suri V., Idilman R., Barclay S.T., Dou X., Berg T., Hayes P.C., Flaherty J.F., Zhou Y., Zhang Z., Buti M., Hutchinson S.J., Guo Y., Calleja J.L., Lin L., Zhao L., Chen Y., Janssen H.L.A., Zhu C., Shi L., Tang X., Gaggar A., Wei L., Jia J., Irving W.L., Johnson P.J., Lampertico P., Hou J. (2020)

Background & Aims: Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HCC risk score to predict the ...

Antiviral Activity of Bee Products

Kontogiannis T., Dimitriou T.G., Didaras N.A., Mossialos D. (2022)

Honey bees provide many products exerting a wide range of benefits to humans. Honey, propolis, royal jelly, beeswax, bee venom, bee pollen and bee bread have been used as natural medicines since ancient times because of ...

Antiviral unsaturates nucleosides

Komiotis, D.; Manta, S.; Tsoukala, E.; Tzioumaki, N. (2008)

In the search for effective, selective and nontoxic antiviral agents, a variety of nucleoside analogues have been synthesized, with different functionalities in the carbohydrate moiety. Unsaturated nucleoside analogues are ...

Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome

Keskin O., Wedemeyer H., Tüzün A., Zachou K., Deda X., Dalekos G.N., Heidrich B., Pehlivan S., Zeuzem S., Yalçin K., Gürel S., Tabak F., Idilman R., Bozkaya H., Manns M., Yurdaydin C. (2015)

Background & Aims: Interferon is the only effective treatment for chronic hepatitis D virus (HDV) infection. No rules have been set for stopping treatment based on viral kinetics. We analyzed data from an international ...

Checkpoint modulation in chronic hepatitis B: From hypothesis to approval

Germanidis G., Hytiroglou P., Vassiliadis T., Speletas M. (2018)

[No abstract available]

Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN)

Wranke A., Pinheiro Borzacov L.M., Parana R., Lobato C., Hamid S., Ceausu E., Dalekos G.N., Rizzetto M., Turcanu A., Niro G.A., Lubna F., Abbas M., Ingiliz P., Buti M., Ferenci P., Vanwolleghem T., Hayden T., Dashdorj N., Motoc A., Cornberg M., Abbas Z., Yurdaydin C., Manns M.P., Wedemeyer H., Hardtke S., Serrano B., Wöbse M., Heidrich B., Muche M., Gatselis N., Zachou K., Ho E., Smedile A., Fontana R., Gish R., Obretin D., Stern R., the Hepatitis Delta International Network (2018)

Background & Aims: Chronic hepatitis D (delta) is a major global health burden. Clinical and virological characteristics of patients with hepatitis D virus (HDV) infection and treatment approaches in different regions ...

Conformational properties of HIV-1 gp120/V3 immunogenic domains

Galanakis, P. A.; Spyroulias, G. A.; Rizos, A.; Samolis, P.; Krambovitis, E. (2005)

Infection of target host cells by the human immunodeficiency virus-1 (HIV-1) is a multi-step process involving a series of conformational changes in the viral gp120 and gp41 proteins. Gp120 binding to the main cell receptor, ...

Design, synthesis, and biological evaluation of novel C5-modified pyrimidine ribofuranonucleosides as potential antitumor or/and antiviral agents

Kollatos N., Mitsos C., Manta S., Tzioumaki N., Giannakas C., Alexouli T., Panagiotopoulou A., Schols D., Andrei G., Komiotis D. (2020)

Background: Nucleoside analogues are well-known antitumor, antiviral, and chemotherapeutic agents. Alterations on both their sugar and the heterocyclic parts may lead to significant changes in the spectrum of their biological ...

Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population

Papatheodoridis G.V., Sypsa V., Dalekos G., Yurdaydin C., van Boemmel F., Buti M., Goulis J., Calleja J.L., Chi H., Manolakopoulos S., Loglio A., Siakavellas S., Gatselis N., Keskın O., Lehretz M., Savvidou S., de la Revilla J., Hansen B.E., Kourikou A., Vlachogiannakos I., Galanis K., Idilman R., Colombo M., Esteban R., Janssen H.L.A., Berg T., Lampertico P. (2018)

Background & Aims: The effects of long-term antiviral therapy on survival have not been adequately assessed in chronic hepatitis B (CHB). In this 10-centre, ongoing cohort study, we evaluated the probability of survival ...

Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B

Papatheodoridis G.V., Sypsa V., Dalekos G.N., Yurdaydin C., Van Boemmel F., Buti M., Calleja J.L., Chi H., Goulis J., Manolakopoulos S., Loglio A., Voulgaris T., Gatselis N., Keskin O., Veelken R., Lopez-Gomez M., Hansen B.E., Savvidou S., Kourikou A., Vlachogiannakos J., Galanis K., Idilman R., Esteban R., Janssen H.L.A., Berg T., Lampertico P. (2020)

Background & Aims: Hepatocellular carcinoma (HCC) may develop in patients with chronic hepatitis (CHB) even after 5 years of oral therapy and cannot be easily predicted. We assessed predictors of HCC development and the ...

Host – virus – drug interactions as determinants of COVID-19’s phenotypes: A data-driven hypothesis

Vavougios G.D. (2020)

There is a growing body of evidence on the significance of interactions between comorbidities, their treatments and COVID-19 clinical phenotypes. The hypothesis explored herein is that pharmaceutical compounds currently ...

Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials

Tasoudis P.T., Arvaniti C.K., Adamou A.T., Belios I., Stone J.H., Horick N., Sagris D., Dalekos G.N., Ntaios G. (2022)

Objective: To assess the efficacy of IL-6 inhibitors compared to standard of care (SOC) in COVID-19 patients. Data Sources: A systematic review of the MEDLINE and Scopus databases (last search: October 8th, 2021) was ...

Medical-grade honey outperforms conventional treatments for healing cold sores—A clinical study

Naik P.P., Mossialos D., van Wijk B., Novakova P., Wagener F.A.D.T.G., Cremers N.A.J. (2021)

Cold sores are nasolabial blisters caused by herpes simplex virus (HSV) infections. Novel therapies demonstrating simultaneously antiviral activity and improved wound healing are war-ranted. The aim of this study was to ...

PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy

Papatheodoridis G., Dalekos G., Sypsa V., Yurdaydin C., Buti M., Goulis J., Calleja J.L., Chi H., Manolakopoulos S., Mangia G., Gatselis N., Keskin O., Savvidou S., De La Revilla J., Hansen B.E., Vlachogiannakos I., Galanis K., Idilman R., Colombo M., Esteban R., Janssen H.L.A., Lampertico P. (2016)

Background & Aims Risk scores for hepatocellular carcinoma (HCC) developed in Asians offer poor-moderate predictability in Caucasian patients with chronic hepatitis B (CHB). This nine center cohort study aimed to develop ...

Patients with haemoglobinopathies and chronic hepatitis C: A real difficult to treat population in 2016?

Zachou K., Arvaniti P., Gatselis N.K., Azariadis K., Papadamou G., Rigopoulou E., Dalekos G.N. (2017)

Background & objectives: In the past, patients with haemoglobinopathies were at high risk of acquiring hepatitis C virus (HCV) due to multiple transfusions before HCV screening. In these patients, the coexistence of ...

Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry

Giannis D., Allen S.L., Tsang J., Flint S., Pinhasov T., Williams S., Tan G., Thakur R., Leung C., Snyder M., Bhatia C., Garrett D., Cotte C., Isaacs S., Gugerty E., Davidson A., Marder G.S., Schnitzer A., Goldberg B., McGinn T., Davidson K.W., Barish M.A., Qiu M., Zhang M., Goldin M., Matsagkas M., Arnaoutoglou E., Spyropoulos A.C. (2021)

Thromboembolic events, including venous thromboembolism (VTE) and arterial thromboembolism (ATE), and mortality from subclinical thrombotic events occur frequently in coronavirus disease 2019 (COVID-19) inpatients. Whether ...

Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B

Papatheodoridi M., Hadziyannis E., Berby F., Zachou K., Testoni B., Rigopoulou E., Gatselis N.K., Lyberopoulou A., Vlachogiannakos I., Manolakopoulos S., Dalekos G.N., Zoulim F., Papatheodoridis G.V. (2020)

Reliable predictors of outcomes after treatment discontinuation in HBeAg-negative chronic hepatitis B (CHB) patients have not been established. We investigated the role of hepatitis B surface antigen (HBsAg), interferon-inducible ...

Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice

Papatheodoridi M., Dalekos G.N., Goulis J., Manolakopoulos S., Triantos C., Zachou K., Koukoufiki A., Kourikou A., Zisimopoulos K., Tsoulas C., Papatheodoridis G.V. (2017)

Background We determined the proportions of patients with chronic hepatitis C (CHC) in association with possible prioritized indications for interferon-free regimens and the use of co-medications with potential drug-drug ...

The Remarkable Evolutionary Plasticity of Coronaviruses by Mutation and Recombination: Insights for the COVID-19 Pandemic and the Future Evolutionary Paths of SARS-CoV-2

Amoutzias G.D., Nikolaidis M., Tryfonopoulou E., Chlichlia K., Markoulatos P., Oliver S.G. (2022)

Coronaviruses (CoVs) constitute a large and diverse subfamily of positive-sense sin-gle-stranded RNA viruses. They are found in many mammals and birds and have great importance for the health of humans and farm animals. ...

Aiming towards hepatitis C virus elimination in Greece ﻿

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis ﻿

Antiviral Activity of Bee Products ﻿

Antiviral unsaturates nucleosides ﻿

Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome ﻿

Checkpoint modulation in chronic hepatitis B: From hypothesis to approval ﻿

Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN) ﻿

Conformational properties of HIV-1 gp120/V3 immunogenic domains ﻿

Design, synthesis, and biological evaluation of novel C5-modified pyrimidine ribofuranonucleosides as potential antitumor or/and antiviral agents ﻿

Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population ﻿

Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B ﻿

Host – virus – drug interactions as determinants of COVID-19’s phenotypes: A data-driven hypothesis ﻿

Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials ﻿

Medical-grade honey outperforms conventional treatments for healing cold sores—A clinical study ﻿

PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy ﻿

Patients with haemoglobinopathies and chronic hepatitis C: A real difficult to treat population in 2016? ﻿

Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry ﻿

Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B ﻿

Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice ﻿

The Remarkable Evolutionary Plasticity of Coronaviruses by Mutation and Recombination: Insights for the COVID-19 Pandemic and the Future Evolutionary Paths of SARS-CoV-2 ﻿